121 results about "Spectrum disorder" patented technology

The invention relates to an autism spectrum disorder screening application system which comprises a front-end user interaction device and a background data processing server. The front-end user interaction device comprises a child information management module; the scale screening module is used for providing at least one autism screening scale for the user to select and fill, and generating a scale screening score after receiving a scale answer filled by the user; the photo screening module is used for receiving at least one child front face image uploaded by the user, preprocessing the face image and then calling a photo analysis model to generate a photo screening score; the screening process of the front-end user interaction device comprises the steps that after a user selects a target child through the child information management module, operation of the scale screening module and the photo screening module is completed in sequence, and the background data processing server generates a comprehensive score and a risk level for scale screening scores and photo screening scores through a weighted voting mechanism. Through the application system, accurate ASD pre-diagnosis classification can be quickly provided.

The invention relates to the technical field of neuroscience and artificial intelligence, in particular to an autism spectrum disorder prediction method based on EEG machine learning, which comprises the following steps: step 1, collecting EEG data for children with autism spectrum disorder and healthy control children; step 2, preprocessing the collected EEG data, then extracting sleep spindle wave signals in the EEG data, and analyzing the sleep spindle wave signals to obtain feature information data; step 3, performing standardization processing on the obtained feature information data to obtain a data set, and then dividing the data set into a training set and a test set; 4, training the training set through different machine learning algorithms to obtain corresponding training models, and selecting an optimal model from the training models through a five-fold cross validation strategy; and 5, inputting the test set into each optimal model for evaluation, and comparing evaluation results to obtain a target model. The method provides a scientific basis for early intervention of ASD.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.

The invention relates to the technical field of medical auxiliary diagnosis, and discloses an ASD auxiliary diagnosis method fusing dynamic low-order and high-order dynamic central moment networks, and the method comprises the steps: obtaining resting state functional magnetic resonance imaging data of a subject, and carrying out the preprocessing; constructing a low-order dynamic function connection network and a high-order dynamic function connection network to respectively describe direct connection and connection collaboration of the brain region; extracting multi-order central moment characteristics of the two types of networks to obtain stable statistics; generating a low-high order dynamic central moment network by adopting a puzzle fusion strategy; inputting the fusion features into a visual Transform model for classification, and outputting an auxiliary diagnosis result of the infantile autism spectrum disorder; and the key brain region is identified by analyzing the attention weight of the model so as to enhance the interpretability. According to the method, multi-level dynamic connection information is effectively fused, the influence of time asynchronism is overcome, the method has the advantages of being high in classification accuracy, high in generalization ability and good in biological interpretation, and a reliable solution is provided for ASD auxiliary diagnosis.

The embodiment of the invention discloses an autism spectrum disorder subtype division method and device, a medium and a program product. The method comprises the following steps: constructing a connection brain map based on neuroimaging data and a functional brain region division template of an ASD individual; constructing a brain age regression model, predicting the social brain age of the ASD individual based on the connection brain map and the brain age regression model, and obtaining the brain age difference of the ASD individual in combination with the actual brain age of the ASD individual; obtaining an ADOS social score of the ASD individual, and carrying out clustering analysis on the ADOS social score and the brain age difference to obtain a clustering subtype; and carrying out behavioral verification and neural dimension verification on the clustering subtypes, and constructing a combined portrait among the subtypes, the behavior features and the neural features based on a verification result. According to the method, the social brain age can be predicted by constructing the connection brain map, the clustering subtypes are divided, the combined portrait is constructed, a doctor can be accurately assisted to detect ASD subtype neural development differences, and discovery and application of subtype specific biomarkers are assisted.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses a rehabilitation nursing system for treating autism spectrum disorder children based on AI intelligent accompanying. The rehabilitation nursing system comprises an AI intelligent accompanying robot, a multi-mode interaction module, a personalized intervention scheme generation module, a real-time monitoring module and a cloud data platform. The system obtains facial expressions, voices, actions and electroencephalogram signals of a child patient in real time through a camera, a sensor, electroencephalogram equipment and other multi-mode data acquisition modules, emotion recognition is conducted in combination with a convolutional neural network, the emotion state is analyzed through an emotion calculation model, and an autism diagnosis and treatment knowledge base is constructed through a knowledge graph. The system generates a personalized intervention scheme based on a deep learning algorithm, and dynamically adjusts the training difficulty through real-time intervention means such as virtual coaches, action correction, dialogue guidance and the like in combination with reinforcement learning. The system provides an efficient and personalized home rehabilitation solution for children with autism, the social ability is improved, and the rehabilitation period is shortened.

The invention discloses an autism child attention prediction method based on a Mamb-Unet structure, and the method comprises the steps: constructing a multi-modal data set for autism child attention prediction, constructing an autism child attention prediction model based on the Mamb-Unet structure, and training the model; and performing atypical visual attention prediction on a to-be-detected image by using the trained model to obtain a prediction result. The model comprises a preprocessing module, an encoder part, a bottleneck part, a decoder part and an output part which are connected in sequence, wherein an efficient self-adaptive visual state space block, a frequency domain attention module, a conditional visual state space block and a conditional attention fusion module are arranged; the output of the encoder portion is also propagated through a hopping connection to the decoder portion. According to the method, the autism spectrum disorder atypical visual attention prediction accuracy is remarkably improved.

The application relates to the technical field of image recognition, in particular to a children autism spectrum disorder stereotyped behavior recognition system based on video images. The system screens target pixel points from pixel points; determines a motion intensity index according to a trajectory point sequence of the target pixel points; converts the trajectory point sequence of the target pixel points into a motion vector sequence; determines direction similarity according to direction similarity between vectors; clusters the vectors based on the direction similarity, and identifies a target cluster; determines a motion regularity index according to the number of vectors in the target cluster and the direction similarity; determines a saliency index in combination with the motion intensity index; clusters the target pixel points based on the saliency index, and sets a region of interest; determines an enhancement weight according to the density of the target pixel points in the region and the saliency index; and determines a total enhancement demand value in combination with the gray scale and gradient features of the pixel points in the region; and reversely maps the total enhancement demand value into a gamma correction parameter, so that the accuracy of recognition is improved.

Compositions and methods for treating autism spectrum disorder, obsessive compulsive disorder or tics with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of autism spectrum disorder, obsessive compulsive disorder or tics. (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

A method for early diagnosis of autism spectrum disorder (ASD) including determining an ASD risk index, determining an ASD brain index that includes administering at least one auditory brainstem response (ABR) test to an ear canal of a patient, producing a plurality of biomarkers and identifying at least one biomarker of the plurality of biomarkers as a potential ASD biomarker, and determining an ASD likelihood responsive to each of the ASD risk index and ASD brain index.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

Provided is an AAV vector capable of expressing a human Mef2c gene in the brain. Specifically, provided are an adeno-associated virus vector capable of expressing a full-length MEF2C protein, and the use thereof. The adeno-associated virus vector can significantly ameliorate the social deficit symptoms of mice with Mef2c gene deletion.

To provide a more effective medicine for treating ASD.SOLUTION: A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 1a receptor antagonist. A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 30IU receptor antagonist. A therapeutic agent for autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 1a receptor; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the pharmaceutical composition comprises an oxytocin-receptor agonist and a vasopressin 1a receptor antagonist as active ingredients; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 30IU receptor; and a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the vasopressin-receptor antagonist is SR49059. 1a.SELECTED DRAWING: None

In some embodiments, a composition comprising Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus plantarum, and Streptococcus thermophilus is provided. In some embodiments, provided is the use of a composition of any of the examples herein for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorder (ASD), anxiety disorder and / or gastrointestinal (GI) disorder or condition, enhancing attention and / or concentration, or stimulating a GABA receptor in a subject. In some embodiments, methods and kits are provided for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorders, anxiety disorders, and / or gastrointestinal disorders or conditions, enhancing attention and / or concentration, or stimulating GABA receptors in a subject. In certain embodiments, the compositions are safe to use and effective to prevent or alleviate anxiety and / or sensory hypersensitivity in subjects, particularly children subjects.

The present invention relates to non-peptide agonists of the oxytocin receptor of formula (I), to pharmaceutical compositions comprising said compounds and a pharmaceutically acceptable vehicle, and in particular to said compounds for the treatment of any known condition in which oxytocin has a beneficial effect, such as autism spectrum disorder, in particular for the treatment of social interaction disorders in autism spectrum disorder. TIFF2025537920000040.tif49170

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.

The present disclosure provides methods of treating Autism Spectrum Disorder. More particularly, the present disclosure relates to methods of using cord blood tissue-derived mesenchymal stromal cells (hCT-MSCs) to treat Autism Spectrum Disorder. The methods involve treating a patient having or suspected of having an Autism Spectrum Disorder by administering a therapeutically effective amount of hCT-MSCs.

The present invention relates to a system for early screening of autism spectrum disorder using eye tracking. According to the present invention, autism spectrum disorder may be diagnosed early by applying response data of a user's gaze, which reacts to images or videos outputted on a display, to an autism spectrum disorder screening model. In addition, the present invention may be used to easily check a degree of suspicion of autism spectrum disorder at home, and thus may be utilized in the fields of early diagnosis, prevention, and treatment of autism in children.

This invention discloses the application of Compound C108 in the preparation of drugs for treating autism spectrum disorder, belonging to the biomedical field. Experimental studies have demonstrated that SGs (sigma cells) are key factors involved in the formation of autism caused by genetic mutations and environmental factors. Compound C108 can inhibit SG levels by intervening in G3BP2 protein expression, ultimately alleviating autistic social behaviors. Therefore, Compound C108 can serve as a novel compound for preparing drugs to treat autistic social disorders.

This invention relates to the field of biomedical technology, specifically disclosing the application of betaine in the preparation of drugs for treating autism. Through experiments using a valproic acid-induced mouse model of autism spectrum disorder, this invention found that betaine can significantly improve social impairments and repetitive, stereotyped behaviors in the model mice, and exhibits stable and reproducible effects in both 1-month-old and 2-month-old male offspring. This invention reveals a novel use of betaine in treating core behavioral deficits in autism spectrum disorder (ASD), providing a new source of natural active ingredients for the preparation of drugs for treating autism.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present application is applicable to the field of medical diagnosis technology, and provides a diagnostic processing method and system for autism spectrum disorder, the method comprising: obtaining EEG signal data and eye movement thermal images of a person to be diagnosed in multiple diagnostic tasks; performing feature extraction on the EEG signal data and eye movement thermal images of the multiple diagnostic tasks according to preset extraction conditions, to obtain EEG feature vectors and eye movement features of the multiple diagnostic tasks; cross-fusing the EEG feature vectors and eye movement features of the multiple diagnostic tasks, to obtain multimodal fusion attention features of the multiple diagnostic tasks; classifying and predicting the multiple multimodal fusion attention features, to obtain a diagnostic result for the person to be diagnosed, thereby solving the problems of the prior art in the diagnosis of people with autism spectrum disorder, which are highly subjective, have a high misdiagnosis rate, and have limitations in data processing due to reliance on behavioral observation and questionnaire surveys.

The invention relates generally to the treatment of autism spectrum disorder (ASD) and sleep disturbances and, more particularly, to the treatment of sleep disorders and / or the improvement of daytime functioning in ASD patients using tasimelteon.